{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T08:45:19Z","timestamp":1772268319121,"version":"3.50.1"},"reference-count":23,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007632","name":"Changhua Christian Hospital","doi-asserted-by":"crossref","award":["110-CCH-IRP-040"],"award-info":[{"award-number":["110-CCH-IRP-040"]}],"id":[{"id":"10.13039\/501100007632","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tenofovir alafenamide (TAF) has good viral suppression efficacy and less adverse effect than tenofovir disoproxil fumarate (TDF). Real-world studies on the antiviral efficacy and safety of switching from TDF to TAF in patients with chronic hepatitis B (CHB) are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study included 167 nucleos(t)ide analogue (NA)-naive patients with CHB. All the patients received TDF at least 12 months before switching and TAF at least 12 months after switching at a single medical center. The Friedman test with Dunn\u2013Bonferroni\n                      <jats:italic>post hoc<\/jats:italic>\n                      tests and repeated-measures analysis of variance was used to analyze the effect of complete viral suppression, alanine aminotransferase (ALT) level normalization, renal function changes, body weight, and body mass index in the periods before and after switching.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean age and TDF treatment duration were 52 \u00b1 11 years and 2.8 years (interquartile range, 1.51\u20135.15 years), respectively. The complete viral suppression rate was similar between the time of switching and 48 weeks after switching to TAF (77.8%\n                      <jats:italic>vs<\/jats:italic>\n                      76%,\n                      <jats:italic>P<\/jats:italic>\n                      = 1.000). The percentage of alanine aminotransferase (ALT) normalization increased from 26.3% at TDF start to 81.4% (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001) at time of switching and 89.2% at 48 weeks after switching to TAF (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.428). The median estimated glomerular filtration rate decreased from 100.09 mL\/min\/1.73 m\u00b2 at TDF start to 91.97 mL\/min\/1.73 m\u00b2 (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001) at the time of switching and stabilized at 48 weeks after switching to TAF (93.47 mL\/min\/1.73m\u00b2,\n                      <jats:italic>P<\/jats:italic>\n                      = 1.000). The body weight decreased from 69.2 \u00b1 12.2 kg at TDF start to 67.4 \u00b1 12.1 kg (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001) at the time of switching to TAF and returned to 68.7 \u00b1 12.7 kg (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001) 48 weeks thereafter. The body mass index (BMI) decreased from 25 \u00b1 3.3 kg\/m\u00b2 at TDF start to 24.5 \u00b1 3.3 kg\/m\u00b2 (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.002) at the time of switching to TAF and returned to 25.1 \u00b1 3.6 kg\/m\u00b2 (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001) 48 weeks thereafter.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study showed that switching to TAF from TDF had good antiviral effectiveness and stabilized renal function. The body weight and BMI decreased during TDF therapy and regained after switching to TAF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.7717\/peerj.12527","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T06:33:45Z","timestamp":1637303625000},"page":"e12527","source":"Crossref","is-referenced-by-count":9,"title":["Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study"],"prefix":"10.7717","volume":"9","author":[{"given":"Pei-Yuan","family":"Su","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Changhua Christian Hospital, Changhua, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5554-5938","authenticated-orcid":true,"given":"Wei-Wen","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Changhua Christian Hospital, Changhua, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chun","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Changhua Christian Hospital, Changhua, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1021-2114","authenticated-orcid":true,"given":"Siou-Ping","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Changhua Christian Hospital, Changhua, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3494-2245","authenticated-orcid":true,"given":"Hsu-Heng","family":"Yen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Changhua Christian Hospital, Changhua, Taiwan"},{"name":"Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan"},{"name":"General Education Center, Chienkuo Technology University, Changhua, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4443","published-online":{"date-parts":[[2021,11,19]]},"reference":[{"issue":"4","key":"10.7717\/peerj.12527\/ref-1","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"Journal of Hepatology"},{"key":"10.7717\/peerj.12527\/ref-2","doi-asserted-by":"publisher","first-page":"e10380","DOI":"10.7759\/cureus.10380","article-title":"Clinical characteristics of hepatitis b virus patients after switching to tenofovir alafenamide fumarate: a retrospective observational study","volume":"17","author":"Alghamdi","year":"2020","journal-title":"Cureus"},{"key":"10.7717\/peerj.12527\/ref-3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10620-021-07033-y","article-title":"Safety and effectiveness of tenofovir alafenamide in usual clinical practice confirms results of clinical trials: TARGET-HBV","volume":"63","author":"Bernstein","year":"2021","journal-title":"Digestive Diseases and Sciences"},{"issue":"3","key":"10.7717\/peerj.12527\/ref-4","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"10.7717\/peerj.12527\/ref-5","doi-asserted-by":"publisher","first-page":"S1542","DOI":"10.1016\/j.cgh.2021.04.045","article-title":"Tenofovir alafenamide for drug-resistant hepatitis B: a randomized trial for switching from tenofovir disoproxil fumarate","volume":"44","author":"Byun","year":"2021","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"3","key":"10.7717\/peerj.12527\/ref-6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"6","key":"10.7717\/peerj.12527\/ref-7","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/jvh.13500","article-title":"Effectiveness and renal safety of tenofovir alafenamide fumarate among chronic hepatitis b patients: real-world study","volume":"28","author":"Farag","year":"2021","journal-title":"Journal of Viral Hepatitis"},{"issue":"1","key":"10.7717\/peerj.12527\/ref-8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s15010-018-1227-0","article-title":"A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)-to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015\u20132017","volume":"47","author":"Gomez","year":"2019","journal-title":"Infection"},{"issue":"1","key":"10.7717\/peerj.12527\/ref-9","doi-asserted-by":"publisher","first-page":"ofw009","DOI":"10.1093\/ofid\/ofw009","article-title":"Antiretroviral drugs and risk of chronic alanine aminotransferase elevation in human immunodeficiency virus (HIV)-monoinfected persons: the data collection on adverse events of anti-HIV drugs study","volume":"3","author":"Kovari","year":"2016","journal-title":"Open Forum Infectious Diseases"},{"issue":"2","key":"10.7717\/peerj.12527\/ref-10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.7717\/peerj.12527\/ref-11","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study","volume":"5","author":"Lampertico","year":"2020","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"2","key":"10.7717\/peerj.12527\/ref-12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/jgh3.12481","article-title":"Bone and renal safety profile at 72 weeks after switching to tenofovir alafenamide in chronic hepatitis B patients","volume":"5","author":"Lee","year":"2021","journal-title":"JGH Open"},{"issue":"9","key":"10.7717\/peerj.12527\/ref-13","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.7717\/peerj.12527\/ref-14","doi-asserted-by":"publisher","first-page":"e25702","DOI":"10.1002\/jia2.25702","article-title":"Weight gain before and after switch from TDF to TAF in a US cohort study","volume":"24","author":"Mallon","year":"2021","journal-title":"Journal of The International Aids Society"},{"issue":"3","key":"10.7717\/peerj.12527\/ref-15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3390\/life11030263","article-title":"Tenofovir alafenamide rescues renal tubules in patients with chronic hepatitis B","volume":"11","author":"Sano","year":"2021","journal-title":"Life"},{"issue":"10","key":"10.7717\/peerj.12527\/ref-16","doi-asserted-by":"publisher","first-page":"ofz414","DOI":"10.1093\/ofid\/ofz414","article-title":"Changes in body mass index and atherosclerotic disease risk score after switching from tenofovir disoproxil fumarate to tenofovir alafenamide","volume":"6","author":"Schafer","year":"2019","journal-title":"Open Forum Infectious Diseases"},{"issue":"2","key":"10.7717\/peerj.12527\/ref-17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/QAI.0000000000002429","article-title":"Brief report: switching from TDF to TAF in HIV\/HBV-coinfected individuals with renal dysfunction-a prospective cohort study","volume":"85","author":"Surial","year":"2020","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"issue":"6","key":"10.7717\/peerj.12527\/ref-18","doi-asserted-by":"publisher","first-page":"758","DOI":"10.7326\/M20-4853","article-title":"Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV","volume":"174","author":"Surial","year":"2021","journal-title":"Annals of Internal Medicine"},{"issue":"17","key":"10.7717\/peerj.12527\/ref-19","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1001\/jama.2018.3795","article-title":"Chronic hepatitis B infection a review","volume":"319","author":"Tang","year":"2018","journal-title":"JAMA"},{"issue":"4","key":"10.7717\/peerj.12527\/ref-20","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD, 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.7717\/peerj.12527\/ref-21","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/hep.31793","article-title":"Treatment and renal outcomes up to 96 weeks after tenofovir alafenamide switch from tenofovir disoproxil fumarate in routine practice, Online ahead of print","volume":"74","author":"Toyoda","year":"2021","journal-title":"Hepatology"},{"key":"10.7717\/peerj.12527\/ref-22","article-title":"Global hepatitis report","author":"WHO","year":"2017"},{"issue":"1","key":"10.7717\/peerj.12527\/ref-23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2018.35","article-title":"Hepatitis B virus infection","volume":"4","author":"Yuen","year":"2018","journal-title":"Nature Reviews Disease Primers"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/12527.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/12527.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/12527.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/12527.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T06:33:50Z","timestamp":1637303630000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/12527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,19]]},"references-count":23,"alternative-id":["10.7717\/peerj.12527"],"URL":"https:\/\/doi.org\/10.7717\/peerj.12527","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.7287\/peerj.12527v0.1\/reviews\/1","asserted-by":"object"},{"id-type":"doi","id":"10.7287\/peerj.12527v0.1\/reviews\/2","asserted-by":"object"}]},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,19]]},"article-number":"e12527"}}